How much did bioXXmed achieve in EBIT for the current year?
In the current year, bioXXmed has achieved an EBIT of -888,800 EUR.
bioXXmed EBIT 2024
bioXXmed EBIT
-888,800 EUR
Ticker
T5O.DE
ISIN
DE000A0KFRJ1
WKN
A0KFRJ
In 2024, bioXXmed's EBIT was -888,800 EUR, a 6.02% increase from the -838,300 EUR EBIT recorded in the previous year.
The bioXXmed EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2025e | - |
| 2024e | - |
| 2023e | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
| 2004 | - |
| 2003 | - |
| 2002 | - |
bioXXmed Revenue, EBIT, Net Income DE000A0KFRJ1 · A0KFRJ
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into bioXXmed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by bioXXmed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects bioXXmed’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of bioXXmed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into bioXXmed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing bioXXmed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on bioXXmed’s growth potential.
bioXXmed Revenue, EBIT and net profit per share
| Date | bioXXmed Revenue | bioXXmed EBIT | bioXXmed Net Income |
|---|---|---|---|
| 2025e | 548.01 M undefined | -919,100 undefined | -3.83 M undefined |
| 2024e | 138.39 M undefined | -888,800 undefined | -4.09 M undefined |
| 2023e | 15,150 undefined | -838,300 undefined | -4.09 M undefined |
| 2022 | 12,230 undefined | -823,000 undefined | -829,840 undefined |
| 2021 | 44,630 undefined | -1.53 M undefined | -4.06 M undefined |
| 2020 | 36,000 undefined | -1.84 M undefined | -1.84 M undefined |
| 2019 | 36,180 undefined | -1.17 M undefined | -1.27 M undefined |
| 2018 | 0 undefined | -1.22 M undefined | -1.42 M undefined |
| 2017 | 89,820 undefined | -1.02 M undefined | -1.07 M undefined |
| 2016 | 0 undefined | -978,450 undefined | -978,680 undefined |
| 2015 | 0 undefined | -1.3 M undefined | -1.3 M undefined |
| 2013 | 50,000 undefined | -1.16 M undefined | -1.14 M undefined |
| 2012 | 50,000 undefined | -690,000 undefined | -660,000 undefined |
| 2011 | 50,000 undefined | -840,000 undefined | -820,000 undefined |
| 2010 | 50,000 undefined | -640,000 undefined | -660,000 undefined |
| 2009 | 50,000 undefined | -610,000 undefined | -810,000 undefined |
| 2008 | 60,000 undefined | -910,000 undefined | -920,000 undefined |
| 2007 | 70,000 undefined | -570,000 undefined | -510,000 undefined |
| 2006 | 120,000 undefined | -500,000 undefined | -480,000 undefined |
| 2005 | 70,000 undefined | -40,000 undefined | -40,000 undefined |
| 2004 | 30,000 undefined | -130,000 undefined | -130,000 undefined |
| 2003 | 0 undefined | -260,000 undefined | -260,000 undefined |
| 2002 | 0 undefined | -490,000 undefined | -480,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2002 | 0 EUR | -490,000 EUR | -480,000 EUR |
| 2003 | 0 EUR | -260,000 EUR | -260,000 EUR |
| 2004 | 30,000 EUR | -130,000 EUR | -130,000 EUR |
| 2005 | 70,000 EUR | -40,000 EUR | -40,000 EUR |
| 2006 | 120,000 EUR | -500,000 EUR | -480,000 EUR |
| 2007 | 70,000 EUR | -570,000 EUR | -510,000 EUR |
| 2008 | 60,000 EUR | -910,000 EUR | -920,000 EUR |
| 2009 | 50,000 EUR | -610,000 EUR | -810,000 EUR |
| 2010 | 50,000 EUR | -640,000 EUR | -660,000 EUR |
| 2011 | 50,000 EUR | -840,000 EUR | -820,000 EUR |
| 2012 | 50,000 EUR | -690,000 EUR | -660,000 EUR |
| 2013 | 50,000 EUR | -1.16 M EUR | -1.14 M EUR |
| 2015 | 0 EUR | -1.3 M EUR | -1.3 M EUR |
| 2016 | 0 EUR | -978,450 EUR | -978,680 EUR |
| 2017 | 89,820 EUR | -1.02 M EUR | -1.07 M EUR |
| 2018 | 0 EUR | -1.22 M EUR | -1.42 M EUR |
| 2019 | 36,180 EUR | -1.17 M EUR | -1.27 M EUR |
| 2020 | 36,000 EUR | -1.84 M EUR | -1.84 M EUR |
| 2021 | 44,630 EUR | -1.53 M EUR | -4.06 M EUR |
| 2022 | 12,230 EUR | -823,000 EUR | -829,840 EUR |
| 2023e | 15,150 EUR | -838,300 EUR | -4.09 M EUR |
| 2024e | 138.39 M EUR | -888,800 EUR | -4.09 M EUR |
| 2025e | 548.01 M EUR | -919,100 EUR | -3.83 M EUR |
bioXXmed stock margins DE000A0KFRJ1 · A0KFRJ
The bioXXmed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of bioXXmed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for bioXXmed.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the bioXXmed's sales revenue. A higher gross margin percentage indicates that the bioXXmed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the bioXXmed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the bioXXmed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the bioXXmed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the bioXXmed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the bioXXmed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
bioXXmed Margin History
| bioXXmed Gross margin | bioXXmed Profit margin | bioXXmed EBIT margin | bioXXmed Profit margin |
|---|---|---|---|
| 2025e | 100 % | -0.17 % | -0.7 % |
| 2024e | 100 % | -0.64 % | -2.95 % |
| 2023e | 100 % | -5,533.33 % | -26,986.67 % |
| 2022 | 100 % | -6,729.35 % | -6,785.28 % |
| 2021 | 100 % | -3,425.88 % | -9,094.62 % |
| 2020 | 100 % | -5,106 % | -5,108.89 % |
| 2019 | 100 % | -3,247.07 % | -3,523.88 % |
| 2018 | 100 % | 0 % | 0 % |
| 2017 | 100 % | -1,132.43 % | -1,185.94 % |
| 2016 | 100 % | 0 % | 0 % |
| 2015 | 100 % | 0 % | 0 % |
| 2013 | 100 % | -2,320 % | -2,280 % |
| 2012 | 100 % | -1,380 % | -1,320 % |
| 2011 | 100 % | -1,680 % | -1,640 % |
| 2010 | 100 % | -1,280 % | -1,320 % |
| 2009 | 100 % | -1,220 % | -1,620 % |
| 2008 | 100 % | -1,516.67 % | -1,533.33 % |
| 2007 | 100 % | -814.29 % | -728.57 % |
| 2006 | 100 % | -416.67 % | -400 % |
| 2005 | 100 % | -57.14 % | -57.14 % |
| 2004 | 100 % | -433.33 % | -433.33 % |
| 2003 | 100 % | 0 % | 0 % |
| 2002 | 100 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2002 | 100 % | 0 % | 0 % |
| 2003 | 100 % | 0 % | 0 % |
| 2004 | 100 % | -433.33 % | -433.33 % |
| 2005 | 100 % | -57.14 % | -57.14 % |
| 2006 | 100 % | -416.67 % | -400 % |
| 2007 | 100 % | -814.29 % | -728.57 % |
| 2008 | 100 % | -1,516.67 % | -1,533.33 % |
| 2009 | 100 % | -1,220 % | -1,620 % |
| 2010 | 100 % | -1,280 % | -1,320 % |
| 2011 | 100 % | -1,680 % | -1,640 % |
| 2012 | 100 % | -1,380 % | -1,320 % |
| 2013 | 100 % | -2,320 % | -2,280 % |
| 2015 | 100 % | 0 % | 0 % |
| 2016 | 100 % | 0 % | 0 % |
| 2017 | 100 % | -1,132.43 % | -1,185.94 % |
| 2018 | 100 % | 0 % | 0 % |
| 2019 | 100 % | -3,247.07 % | -3,523.88 % |
| 2020 | 100 % | -5,106 % | -5,108.89 % |
| 2021 | 100 % | -3,425.88 % | -9,094.62 % |
| 2022 | 100 % | -6,729.35 % | -6,785.28 % |
| 2023e | 100 % | -5,533.33 % | -26,986.67 % |
| 2024e | 100 % | -0.64 % | -2.95 % |
| 2025e | 100 % | -0.17 % | -0.7 % |
bioXXmed Aktienanalyse
What does bioXXmed do?
CytoTools AG is a German biotechnology company based in Darmstadt. It was founded in 2000 and has been listed on the Frankfurt Stock Exchange since 2006. The company focuses on the development of innovative therapies for diseases that have been difficult or impossible to treat so far. CytoTools relies on the use of active substances developed based on endogenous (body's own) molecules. A particular focus is on the research and development of active substances for the treatment of diseases based on inflammatory processes. CytoTools works closely with international research and development partners in this area. CytoTools' business model is based on the development and marketing of products based on innovative technologies and active substances. As a biotechnology company, it specializes in the development of patent-protected products and pursues a scalable business model. The company is divided into various divisions. In the "Pharmaceuticals" division, CytoTools develops innovative active substances and drugs for the treatment of diseases such as inflammatory diseases, cancer, or diabetes. An example of this is the active substance DermaPro, which can be used to treat chronic wounds. In the "Medical Devices" division, CytoTools develops medical devices for the diagnosis and therapy of diseases. An example of this is the CytoSorb system, which is used for extracorporeal blood detoxification and thus supports the treatment of severe infectious and inflammatory diseases. The third division of CytoTools is "Diagnostics". Here, the company develops innovative diagnostic tools for early detection of diseases. An example of this is the biomarker-based rapid test DermaPro Inflammation Score, which allows for a quick and reliable assessment of the inflammatory state of wounds. CytoTools has a strong network of partners and cooperation partners. The most important partners include institutions such as Kiel University, Flensburg University, or the Institute of Molecular Biotechnology in Jena. In addition, CytoTools works closely with international partners from the pharmaceutical industry. Overall, CytoTools is an innovative and rapidly growing biotechnology company specializing in the development of patent-protected products and technologies for the treatment of severe and previously incurable diseases. With its strong network of research and development partners and a wide range of products, the company is well-positioned to continue growing and develop new therapy concepts in the future. bioXXmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing bioXXmed's EBIT
bioXXmed's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of bioXXmed's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
bioXXmed's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in bioXXmed’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about bioXXmed stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company bioXXmed.
How has the EBIT of bioXXmed developed in recent years?
The EBIT of bioXXmed has increased by 6.024% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company bioXXmed?
The EBIT of bioXXmed is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does bioXXmed pay?
Over the past 12 months, bioXXmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, bioXXmed is expected to pay a dividend of 0 EUR.
What is the dividend yield of bioXXmed?
The current dividend yield of bioXXmed is .
When does bioXXmed pay dividends?
bioXXmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of bioXXmed?
bioXXmed paid dividends every year for the past 0 years.
What is the dividend of bioXXmed?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is bioXXmed located?
bioXXmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von bioXXmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of bioXXmed from 10/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did bioXXmed pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of bioXXmed in the year 2023?
In the year 2023, bioXXmed distributed 0 EUR as dividends.
In which currency does bioXXmed pay out the dividend?
The dividends of bioXXmed are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von bioXXmed
Our stock analysis for bioXXmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of bioXXmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
